10x Genomics Inc Class A
TXG
$0.90 (1.91%)
1D
1W
3M
1Y
5Y
ALL
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Zacks Investment Research • 3 hours ago • TXG
10x Genomics (TXG) Upgraded to Buy: Here's Why
Zacks Investment Research • 5 days ago • TXG
10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
PRNewsWire • 6 days ago • TXG
10x Genomics and Lausanne University Hospital Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies for Cancer Care
PRNewsWire • 20 days ago • TXG
10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026
Zacks Investment Research • about 2 months ago • TXG
10x Genomics, Cleveland Clinic Team Up on Bladder Cancer Diagnostics
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.